argenx SE (EBR:ARGX)
Belgium
· Delayed Price · Currency is EUR | Market Cap | 34.09B |
| Revenue (ttm) | 2.17B |
| Net Income (ttm) | 804.63M |
| Shares Out | 60.99M |
| EPS (ttm) | 12.34 |
| PE Ratio | 45.28 |
| Forward PE | 45.48 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 54,808 |
| Average Volume | 102,542 |
| Open | 564.60 |
| Previous Close | 565.00 |
| Day's Range | 559.00 - 570.00 |
| 52-Week Range | 323.40 - 658.00 |
| Beta | 0.20 |
| RSI | 41.34 |
| Earnings Date | May 8, 2025 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]
News
Argenx: The Magic May Be Already Priced In
Argenx is a hold due to limited catalysts in 2025, a rich valuation and clinical risk around label expansion. Read more about ARGX stock here.
P/E Ratio Insights for argenx
Looking into the current session, argenx Inc. (NASDAQ: ARGX) shares are trading at $614.18, after a 0.93% drop. Over the past month, the stock decreased by 4.88% , but over the past year, it actually...
argenx SE (ARGX) Announces Promising Data for VYVGART at AAN Annual Meeting
argenx SE (ARGX) Announces Promising Data for VYVGART at AAN Annual Meeting
argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting
Amsterdam, the Netherlands – March 7, 2025 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, toda...
argenx targets 12,000 CIDP patients with VYVGART expansion in 2025
argenx SE (ARGX) Q4 2024 Earnings Call Transcript
argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent
Earnings Scheduled For February 27, 2025
Companies Reporting Before The Bell • Hafnia (NYSE: HAFN) is estimated to report earnings for its fourth quarter. • argenx (NASDAQ: ARGX) is projected to report quarterly earnings at $1.06 per share...
Argenx beats top-line and bottom-line estimates; initiates FY25 outlook
Argenx SE press release (ARGX): Q4 GAAP EPS of $11.79 beats by $9.92. Revenue of $736.97M (+96.9% Y/Y) beats by $27.15M. Total operating income for the three and twelve months ended
argenx SE (ARGX) Reports Strong Financial Performance and Strategic Advancements in 2024
argenx SE (ARGX) Reports Strong Financial Performance and Strategic Advancements in 2024
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
$737 million in fourth quarter and $2.2 billion in full year global product net sales Received positive CHMP recommendation for VYVGART pre-filled syringe for gMG, enabling launch in the EU; FDA PDUFA...
argenx SE (ARGX) to Present at TD Cowen 45th Annual Healthcare Conference
argenx SE (ARGX) to Present at TD Cowen 45th Annual Healthcare Conference
argenx to Present at TD Cowen 45th Annual Healthcare Conference
February 25, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...
argenx SE (ARGX) Announces Upcoming Conference Call for 2024 Financial Results
argenx SE (ARGX) Announces Upcoming Conference Call for 2024 Financial Results
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
February 20, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...
Argenx Vaults 3,659% With Profit Growth Seen In Triple Digits; Earnings Next As Stock Hits Highs
Argenx recently hit an all-time high ahead of fourth-quarter earnings. Shares are in a flat base with a buy point of 678.21.
argenx: Lofty Valuation Diminishes Appeal Amid Autoimmune Expansion (Rating Downgrade)
Financial writer covers success of Efgartigimod in myositis trials, company's strong revenue and cash position, and future pipeline prospects.
Argenx cut to Sell at Deutsche Bank on valuation
Immunology company argenx estimates higher product net sales from last year
argenx SE (ARGX) Announces Preliminary 2024 Financial Results and Strategic Priorities for 2025
argenx SE (ARGX) Announces Preliminary 2024 Financial Results and Strategic Priorities for 2025
argenx Highlights 2025 Strategic Priorities
Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in fourth quarter sales
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today a...
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 19.58% on an annualized basis producing an average annual return of 32.35%. Currently, argenx has a market capitalization of...
argenx SE (ARGX) Gains Approval for VYVDURA in Japan for CIDP Treatment
argenx SE (ARGX) Gains Approval for VYVDURA in Japan for CIDP Treatment
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy
VYVDURA ® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP